AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Up 661.7% in December

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 205,893 shares, an increase of 661.7% from the December 15th total of 27,032 shares. Based on an average daily volume of 243,723 shares, the short-interest ratio is presently 0.8 days. Currently, 7.2% of the company’s shares are sold short. Currently, 7.2% of the company’s shares are sold short. Based on an average daily volume of 243,723 shares, the short-interest ratio is presently 0.8 days.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of AIM ImmunoTech from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Strong Buy”.

AIM ImmunoTech Trading Down 3.1%

Shares of NYSEAMERICAN:AIM traded down $0.04 during mid-day trading on Monday, reaching $1.25. The stock had a trading volume of 71,284 shares, compared to its average volume of 161,428. The firm has a 50 day simple moving average of $1.40 and a two-hundred day simple moving average of $3.14. AIM ImmunoTech has a twelve month low of $1.07 and a twelve month high of $36.00. The firm has a market cap of $3.56 million, a PE ratio of -0.06 and a beta of 1.21.

AIM ImmunoTech (NYSEAMERICAN:AIM) last issued its earnings results on Monday, November 17th. The company reported ($1.57) EPS for the quarter. The business had revenue of $0.03 million for the quarter. On average, equities analysts anticipate that AIM ImmunoTech will post -0.3 EPS for the current fiscal year.

Institutional Trading of AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Sabby Management LLC bought a new stake in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 28,855 shares of the company’s stock, valued at approximately $79,000. AIM ImmunoTech accounts for about 0.1% of Sabby Management LLC’s portfolio, making the stock its 22nd largest position. Sabby Management LLC owned about 1.06% of AIM ImmunoTech as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.